Anti-TNFα therapy reduced intestinal permeability, alleviated pancreatitis, and improved the expression of IGF2BP3 and CLDN11 in intestinal epithelial cells in experimental obesity-related SAP. This evidence concerns the gene IGF2BP3 and obesity due to melanocortin 4 receptor deficiency.